Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary shares, par value US$0.0001
-
Shares outstanding
-
21,600,641
-
Total 13F shares
-
1,251,879
-
Share change
-
-1,354,964
-
Total reported value
-
$1,063,851
-
Price per share
-
$0.85
-
Number of holders
-
16
-
Value change
-
-$2,036,507
-
Number of buys
-
4
-
Number of sells
-
11
Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary shares, par value US$0.0001 (CASI) as of Q4 2025
As of 31 Dec 2025,
CASI Pharmaceuticals, Inc. - Ordinary shares, par value US$0.0001 (CASI) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,251,879 shares.
The largest 10 holders included
VR ADVISER, LLC, Woodline Partners LP, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, BANK OF AMERICA CORP /DE/, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, ROYAL BANK OF CANADA, UBS Group AG, and WELLS FARGO & COMPANY/MN.
This page lists
16
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.